The Pharmacy of the World
This post was heavily inspired by Insights by Apoorv's breakdown of the same topic. Go watch it. It's what got me down this rabbit hole.
If you have taken a pill today, there is a real chance it was made in India. Not just assembled or packaged in India. Invented through reverse engineering, fought for in courts, and priced at a level that makes it accessible to someone in a small town in Ghana, a hospital in Brazil, or a pharmacy in New Jersey.
That is not an accident. It is the result of fifty years of extraordinarily clever legal thinking, a few courageous scientists who refused to be intimidated by pharmaceutical giants, and a government that consistently chose its people over corporate pressure.
India supplies roughly 20 percent of global generic medicines by volume. It fills 40 percent of all generic drug prescriptions in the United States. It manufactures 60 percent of the world's vaccines. When a child in sub-Saharan Africa gets protected from measles or polio, the odds are better than even that the vaccine came from an Indian facility.
This is the story of how that happened.
India is not just a large manufacturer. It is the single most important source of affordable medicine for the entire world.
of all US generic prescriptions
by volume filled
of global vaccines
by volume manufactured
of UK medicines
supplied from India
of global HIV/AIDS drugs
antiretrovirals by volume
of UNICEF's vaccine needs
annual procurement
Sources: US FDA, WHO, UNICEF, Indian Pharmaceutical Alliance (2024-25 data)
A patent law that changed everything
In 1970, India made a remarkable legal decision. The country was just over two decades old, still finding its economic footing, and the pharmaceutical companies operating within its borders were mostly foreign. Life-saving drugs existed, but they were priced for Western wallets, not Indian incomes.
The government commissioned a review of the patent system and asked a simple question: does this setup serve our people?
The answer was no. The Patents Act of 1970 changed the game entirely.
The key move was distinguishing between "product patents" and "process patents." Under the old British-inherited system, if a company invented a drug molecule, it owned that molecule completely. No one else could make it, regardless of how they made it. India wiped that out for pharmaceuticals and said: you can patent your specific manufacturing method, but not the molecule itself.
This created a legal opening the size of a continent.
Indian scientists could reverse-engineer a molecule (find a chemically distinct new way to make it) and, as long as their process was different, they were entirely within the law. Companies like Cipla and Dr. Reddy's Laboratories became world-class reverse engineers. They developed alternative synthesis pathways, skipping the enormous research and development costs that Western firms had to recover. Costs dropped dramatically. Access expanded. The Indian generic industry was born.
In pharmaceuticals, reverse engineering means figuring out a new way to synthesize a known drug molecule. The end product is chemically identical. The process is different. Under India's 1970 law, this was entirely legal, since India only protected the process, not the final molecule.
By the 1990s, India was not just supplying its own population. It was exporting affordable generic drugs to developing countries across Africa, Asia, and Latin America. The infrastructure was in place. The talent was there. And the legal framework had given it twenty years to grow.
The phone call that shook the world
By 2001, HIV/AIDS was destroying sub-Saharan Africa at a scale that is hard to comprehend today. Millions of people were dying. The treatment existed: a triple-drug cocktail that Western patients were receiving and surviving on. But that treatment cost 15,000 per patient per year. In a continent where many people earned under $500 annually, this was not a healthcare problem. It was a death sentence written in dollars.
Out of the roughly 25 million people infected in Africa at the time, only about 4,000 could afford access to treatment.
Dr. Yusuf Hamied had a different idea. The managing director of Cipla and a chemistry PhD from Cambridge, he had spent years watching India's process patent laws make medicines cheaper domestically. He had already developed Triomune: a single pill combining three critical antiretroviral agents. Because Indian law did not recognize product patents on those molecules, his manufacturing was entirely legal.
The question was price.
On February 6, 2001, a New York Times journalist called Dr. Hamied to confirm a rumor: was Cipla really offering the AIDS drug cocktail for $350 a year? Under a dollar a day?
Yes, said Dr. Hamied.
The story ran the next morning. The global pharmaceutical industry reacted with fury. GlaxoSmithKline's chairman called Indian generic makers "pirates." Western companies threatened legal action. Their argument was earnest: patents exist to fund research, and if you destroy the economics, you destroy the incentive to discover the next drug.
The counterargument was blunter: four thousand people on a continent of hundreds of millions had access to the treatment. That is not a market. That is a catastrophe with a price tag attached to it.
Within months, Western pharmaceutical companies abandoned their lawsuit against the government of South Africa and quietly dropped their own prices. The one-dollar-a-day threshold had shifted the conversation from commercial feasibility to human survival, and there was no going back.
Today, over 80 percent of the antiretroviral drugs used globally to fight HIV/AIDS are supplied by Indian generic manufacturers.
HIV/AIDS triple therapy
Cipla vs. Western multinationals, 2001
On February 7, 2001, the New York Times ran a story that changed global healthcare. Cipla was offering AIDS treatment for under a dollar a day. Over 8 million people in sub-Saharan Africa eventually gained access to life-saving medication because of this moment.
Playing the WTO game brilliantly
In 1991, India nearly went bankrupt. Foreign exchange reserves had fallen to three weeks of import cover. The government flew 47 tonnes of gold to the Bank of England as collateral for an emergency IMF loan. To stabilize the economy, India liberalized and joined the World Trade Organization in 1995.
WTO membership came with a catch: India had to reintroduce product patents for pharmaceuticals. The Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) required it. The generic industry panicked. If every molecule could be patented again, the foundational model of affordable generics would be illegal.
India negotiated a 10-year grace period and spent that decade thinking carefully.
The Patents (Amendment) Act of 2005 reintroduced product patents. But buried inside it was a precision-engineered weapon: Section 3(d).
Section 3(d) says that a minor variation of an existing drug (a new salt, a new crystal form, a new coating) does not qualify for a new patent unless it provides meaningfully better therapeutic performance in the patient. This was aimed directly at "evergreening": filing new patents on slightly tweaked versions of old drugs to extend monopoly protection past the original 20-year term.
Evergreening (what Section 3(d) stops)
Patent expires. Company tweaks the molecule slightly. Files a new 20-year patent. Repeat indefinitely.
Common changes: new salt form, new crystal structure, new coating, new dosage shape. None of these make the drug work better. All were used to restart the patent clock.
India's answer
Show us it actually works better for patients. Or no patent.
Section 3(d) requires that any new form of a known drug demonstrate meaningfully improved therapeutic efficacy. Better shelf life or easier manufacturing does not count. Better outcomes for the patient does.
India had to comply with WTO rules. And it did, technically. But it also built a fence around the most exploitative corporate behavior that those rules allowed.
The Supreme Court said no to Novartis
In 2013, the Supreme Court of India delivered a ruling that the global pharmaceutical industry had not expected.
The case: Novartis AG v. Union of India.
Novartis had a blockbuster leukemia drug called Glivec. The base molecule (imatinib) had been discovered in the early 1990s. Because India had not granted product patents at that time, the original molecule was not patented in India. In 1998, Novartis applied to patent a specific crystal form of the molecule: the beta crystalline form of imatinib mesylate. This form was more stable and easier to manufacture into pills. Novartis wanted a fresh 20-year patent on it.
The Indian Patent Office said no, citing Section 3(d).
The case escalated through the Madras High Court, the Intellectual Property Appellate Board, and finally reached the Supreme Court. Novartis argued the law was vague, arbitrary, and violated India's WTO obligations. They also argued the new crystal form was genuinely different.
The Supreme Court disagreed. The bench ruled that "efficacy" in a pharmaceutical context means therapeutic efficacy, the ability of the drug to produce better results for patients. Better storage stability and easier manufacturing are benefits for the company, not for the patient. Section 3(d) was upheld. The patent was denied.
The practical consequence: Indian manufacturers continued producing generic imatinib at around Rs. 8,000 per month. Had the patent been granted, Novartis would have been charging around Rs. 1,17,000 per month.
The ruling sent a clear signal globally: India's standard for what counts as a meaningful pharmaceutical improvement is stricter than most of the world's, and that strictness is legally sound.
When the government steps in directly
Section 3(d) deals with questionable patents on modified molecules. But what about genuinely innovative drugs, legitimately patented, priced so high that only the very wealthy can afford them?
For those cases, India has Section 84 of the Patents Act: compulsory licensing.
A compulsory license is exactly what it sounds like. If a patented drug is not available at a reasonable price, is not being manufactured in India, and the public need is not being met, the government can legally authorize a domestic company to produce and sell a generic version, paying a fair royalty to the original patent holder. International trade law explicitly permits this under the Doha Declaration.
The first time India used Section 84 was in 2012. The drug was Nexavar (sorafenib tosylate), a treatment for advanced liver and kidney cancer made by the German company Bayer. Bayer's price: Rs. 2,80,438 per month. An Indian generic from Cipla existed on the market for Rs. 27,960. Natco Pharma applied for a compulsory license.
Bayer fought the application hard. Their argument: this damages research incentives. The courts examined the facts. Bayer was importing a minimal quantity of the drug rather than manufacturing it in India. Their Patient Assistance Program covered only a few hundred patients, nowhere near the full public need. And in a Bloomberg interview, Bayer's own CEO had said: "We did not develop this medicine for Indians. We developed it for Western patients who can afford it."
The Patent Controller granted the compulsory license. The courts upheld it. Natco Pharma began selling generic sorafenib for Rs. 8,800 per month, a 97 percent reduction from Bayer's price.
A terminal cancer patient in India went from facing a monthly drug cost of Rs. 2,80,438 (roughly 106). The royalty paid to Bayer ensured the original innovator was still compensated. The patient got to live.
The Nexavar case established something important: patent rights in India are not unconditional. They exist in service of public health. When a patent holder fails to serve that purpose, the state can and will step in.
The supply chain problem nobody talks about
Here is the less celebratory part of the story. And it matters.
India is brilliant at the final stages of drug manufacturing: taking chemical ingredients and turning them into pills, capsules, injectables, and vaccines. The finished products are world-class, rigorously tested, and approved by regulators in the US, EU, and elsewhere.
The ingredients going into those products are a different story.
Active Pharmaceutical Ingredients (APIs) are the chemical compounds that actually do the therapeutic work in a medicine. India's API industry imports approximately $4.35 billion worth of APIs and starting materials every year. About 74 percent of those imports come from China.
For certain antibiotic classes, including penicillin, amoxicillin, cephalosporins, and azithromycin, India's dependence on Chinese API inputs runs between 90 and 100 percent. Even for common medicines like paracetamol and ibuprofen, the raw chemical inputs come largely from Chinese manufacturers.
This dependency was not always the case. In the 1980s and early 1990s, India had a robust domestic API manufacturing base. But China's government invested massively in subsidizing its chemical industry, creating enormous economies of scale. Indian formulation companies gradually found it cheaper to import API from China than to make it domestically. Over two decades, India's capital-intensive fermentation and synthesis capacity quietly hollowed out.
COVID-19 made the vulnerability impossible to ignore. When Chinese factories slowed, supply chains for essential medicines tightened globally within weeks.
India excels at making finished medicines. But the active ingredients inside those medicines come overwhelmingly from one country.
India's PLI scheme has commissioned domestic manufacturing capacity for 28 critical APIs. The goal is full coverage of the 41 most vulnerable ingredients. In FY 2024-25, API exports exceeded API imports for the first time.
■China (dominant source) ■Other countries Data: Ministry of Chemicals, FY 2024-25
India is fixing that too
In 2020, India launched the Production Linked Incentive (PLI) scheme for bulk drugs, committing Rs. 6,940 crore to get Indian companies back into the business of making APIs domestically. The scheme is simple in principle: make more, earn more. Subsidies are tied directly to production output. No production, no incentive.
Three Bulk Drug Parks are being built, in Andhra Pradesh, Gujarat, and Himachal Pradesh, with shared infrastructure (effluent treatment, solvent recovery, power) that makes it economical for companies that could not afford to build standalone facilities.
The results four years in are genuinely encouraging.
Of the 41 critical APIs targeted by the scheme, manufacturing capacity has been commissioned for 28, including some genuinely complex molecules. Penicillin G and Clavulanic Acid (fermentation-derived antibiotics that China had dominated). Dexamethasone, Atorvastatin, Artesunate. The PLI plants have generated cumulative sales of Rs. 2,720 crore and avoided Rs. 2,192 crore in imports. Nearly 5,000 skilled technical jobs have been created.
In FY 2024-25, India's total API exports (Rs. 41,500 crore) exceeded its API imports (Rs. 39,214 crore) for the first time. That is not independence from China on specific critical inputs, not yet. But it is a meaningful turn, and the direction is clear.
India's API dependency on China is not just India's problem. The global pharmaceutical supply chain runs: Chinese chemical parks, to Indian formulation plants, to hospital pharmacies everywhere. Fixing India's API vulnerability is fixing a fragility in global medicine supply.
What comes next
India has won the battle it set out to win in 1970. The country that once imported almost every medicine it needed now supplies the world. The legal architecture built over fifty years (process patents, Section 3(d), compulsory licensing) turned out to be exactly the right combination of tools for this moment in pharmaceutical history.
The next battle is different. Generics are, structurally, a maturing business. The frontier of medicine is moving toward biologics, biosimilars, gene therapies, and targeted immunotherapies. These cannot be reverse-engineered the same way a small-molecule drug can. They require original research, expensive clinical trials, and the kind of institutional risk-taking that is hard to build quickly.
India has the infrastructure. It has the talent pipeline. It has the regulatory experience and deep integration with global supply chains. The question is whether the momentum from the PLI scheme, and the capital accumulated from decades of generic exports, can be redirected toward primary innovation.
If it can, the pharmacy of the world might become the laboratory of the world too. And that would be something to celebrate all over again.
If this was worth sharing, send it to someone on 𝕏 or LinkedIn. Got a question or a thought? Drop me a message — I read everything. If this was worth your time, .